Robert Califf (born September 1951) is a board-certified American cardiologist in Durham, North Carolina. He serves as the the commissioner of the Food and Drug Administration.
Robert Califf Facts
- Full Name: Robert Mckinnon Califf
- Age: 71 years old
- Date of Birth: September 1951
- Place of Birth: Anderson, South Carolina
- Occupation: Cardiologist
- Nationality: American
- Wife: Lydia Califf
Robert Califf Medical School & Residency
- Duke University Hospital, Fellowship Hospital
- UC-San Francisco, Residency Hospital — 1980
- UC-San Francisco, Internship Hospital — 1979
- Duke University, Medical School — 1978
Robert Califf Career
At Duke University School of Medicine, Califf received tenure as a professor of cardiology. The Duke Clinical Research Institute, which has 1000 workers, $320 million in yearly revenue, and 50–60% of its funding coming from the pharmaceutical sector, is regarded as “the largest academic research institution in the world” and was founded by him.
Health outcomes research, research on the quality of healthcare, and translational research—all aimed at ensuring that breakthroughs in science are translated into medical care—have all been led by Califf. In clinical trials examining the effectiveness of the ezetimibe/simvastatin cholesterol-lowering medication combination, he served as the principal investigator.
He was the Duke Translational Medicine Institute (DTMI) head as of 2015 and the vice chancellor for clinical and translational research. With more than 1,200 peer-reviewed articles, Califf is one of the top 10 most-cited authors in the field of medicine according to the Institute for Scientific Information.
In January 2015, Califf was named Deputy Commissioner of the Office of Medical Products and Tobacco at the US Food and Drug Administration, “second in scope only to being commissioner.” In February 2015, Califf was mentioned as a potential replacement for outgoing Food and Drug Administration Commissioner Margaret Hamburg.
In September of that same year, President Barack Obama nominated Califf to take Hamburg’s place as the agency’s new commissioner. By a vote of 89 to 4 in February 2016, the US Senate approved Califf’s appointment as commissioner of the Food and Drug Administration. On January 20, 2017, Dr. Califf resigned as commissioner of the FDA.
President Biden announced his nomination of Califf to take over as FDA director once more on November 12, 2021. On December 14, 2021, he appeared before the Senate HELP committee and answered questions about the pandemic, the opioid problem, and abortion-related topics.
Due to his corporate connections and the drug problem, some Democrats opposed his nomination. A number of Republican senators objected to his appointment because of abortion-related issues. In the end, Califf’s initial nomination was withdrawn and returned to President Biden on January 3, 2022.
The following day, Califf’s nomination was once again sent to the Senate. By a vote of 13-8 on January 13, 2022, he was passed out of committee. By a vote of 50-46 on February 15, 2022, the Senate approved his nomination. On February 17, 2022, Dr. Califf came into office.
Certifications & Licensure
- American Board of Internal Medicine – Certified in Internal Medicine
- American Board of Internal Medicine – Certified in Cardiovascular Disease
- NC State Medical License – Active through 2022
Dr. Robert Mckinnon Califf has the following 14 areas of expertise
- Heart Block
- High Cholesterol
- Acute Coronary Syndrome (ACS)
- Heart Failure
- Heart Attack
- High Cholesterol (Hypercholesterolemia)
- Blood Clot
- Unstable Angina
- Heart Diseases
- Coronary Artery Disease (CAD)
- Blue Cross Blue Shield (BCBS)
- Blue Cross Blue Shield (BCBS) of North Carolina
- Coventry Health Care
- Humana Health
- Multiplan PHCS
Location & Contact Information
2100 Erwin Rd –
Durham, NC 27705
New patients: 800-394-4445, 919-684-8111
Data provided by the National Library of Medicine
- One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial.
- Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy.
- What to do with acute atrial fibrillation?
- Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction.
- Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries.
- Gender differences in survival in advanced heart failure. Insights from the FIRST study.
- Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.
- Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
- Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
- Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).
- Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials.
- Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb)
- A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications.
- Minimal myocardial damage during coronary intervention is associated with impaired outcome.
- Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators.
Robert Califf Net Worth
Robert Califf had an estimated net worth of $10 million.